HDL-C and LDL-C: their role in stroke pathogenesis and implications for treatment.
Elevated serum low-density lipoprotein cholesterol (LDL-C) and low serum high-density lipoprotein cholesterol (HDL-C) are risk factors for atherosclerotic ischemic stroke. The National Cholesterol Education Panel and the American Heart Association have released guidelines for the treatment of dyslipidemia that stress LDL-C reduction using HMG CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (statins) and are applicable to individuals who have had or are at a high risk of having a stroke. Treatment of low HDL-C is a secondary goal of these guidelines and can be best achieved by using extended-release niacin (alone or in combination with statins) and fibrates. Early and aggressive treatment of dyslipidemia is an important component of a multimodality approach to stroke prevention.
Sanossian
Nerses
N
Department of Neurology, University of Southern California, LAC+USC Medical Center, 1200 North State Street, Room 5640, Los Angeles, CA 90033, USA. sanossia@yahoo.com
Tarlov
Nicholas E
NE